Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO)...

Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the...

Dr. Theresa Visarius, VP of Business Development at Immunophotonics, Inc. will be attending 2022 Swiss MedTech Day on Tuesday, June...

Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the Society of Interventional Radiology Annual Scientific...

Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for...

Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today...

The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at...

Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal...

Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into...

Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech...